ArticleCancer research communications2025
Glycemic Control and Prostate Cancer Mortality Risk in Veterans with Type 2 Diabetes Mellitus.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study of veterans diagnosed with diabetes mellitus evaluated the association between time-varying measures of glycemic control and the time to prostate cancer-specific mortality. Competing risk Cox regression models were developed to estimate the association of glycemic control and prostate cancer mortality for the entire sample and stratified by racial and ethnic groups. A total of 763,424 veterans with type 2 diabetes mellitus (T2DM) were included. In the fully adjusted models, moderate glycemic control [hemoglobin A1c (HbA1c) 7%-8%] was associated with a 23% (HR, 0.77; 95% confidence interval, 0.68-0.85) lower risk and poor glycemic control (HbA1c >8%) was associated with a 15% (HR, 0.85; 95% confidence interval, 0.71-0.99) lower risk of prostate cancer mortality compared with good glycemic control (HbA1c <7%), respectively. In the analyses stratified by race and ethnicity, moderate glycemic control was associated with a lower risk of prostate cancer mortality in non-Hispanic White and non-Hispanic Black veterans. SIGNIFICANCE: Unlike many other cancers, there is an inverse association between prostate cancer risk and T2DM diagnosis. In this large, retrospective study of male veterans with T2DM, we observed an inverse association between glycemic control and prostate cancer mortality. Further research is required to verify this relationship in prospective studies and identify the potential mechanisms contributing to these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.